Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.89 |
| ▸ | JAK2 | O60674 | 2/20 | 0.72 |
| ▸ | JAK1 | P23458 | 2/20 | 0.72 |
| ▸ | BRD2 | P25440 | 2/20 | 0.72 |
| ▸ | JAK3 | P52333 | 2/20 | 0.72 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.72 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.72 |
| ▸ | BUB1B | O60566 | 1/20 | 0.72 |
| ▸ | RET | P07949 | 1/20 | 0.72 |
| ▸ | WEE1 | P30291 | 1/20 | 0.72 |
| ▸ | FLT3 | P36888 | 1/20 | 0.72 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17526142 | 0.94 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL30306526 | 0.94 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 | |
| Tert-Butyl Formate SCHEMBL27942882 | 0.93 | BRD4 (0.77) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL31163098 | 0.93 | BRD4 (0.94) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL31163088 | 0.93 | BRD4 (0.94) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL265921 | 0.93 | BRD4 (0.94) | BRD4JAK2JAK1BRD2JAK3 | |
| Hydrochloric Acid SCHEMBL264758 | 0.92 | BRD4 (0.92) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL264965 | 0.92 | BRD4 (0.92) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL264206 | 0.89 | BRD4 (0.73) | BRD4JAK2JAK1BRD2JAK3 | |
| SCHEMBL30306481 | 0.86 | BRD4 (1.00) | BRD4JAK2JAK1BRD2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8604042-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | BRD4 142/4885JAK2 1/4885JAK1 4/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | BRD4 142/4885JAK2 1/4885JAK1 4/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | BRD4 142/4885JAK2 1/4885JAK1 4/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | BRD4 1036/4885JAK2 1/4885JAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.